The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06878404




Registration number
Help: Registration number
NCT06878404
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
13/03/2025
Date registered
Help: Date registered
17/03/2025
Date last updated
Help: Date last updated
3/11/2026

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Scientific title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants With Active Psoriatic Arthritis
Additional trial identifiers [1] 0 0
77242113PSA3001
Additional trial identifiers [2] 0 0
77242113PSA3001
Universal Trial Number (UTN)
Trial acronym
ICONIC-PsA 1
Related trial records

Health condition
Health condition(s) studied:
Arthritis, Psoriatic 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - Icotrokinra
Treatment: Drugs - Placebo
Treatment: Drugs - Active reference comparator

Experimental: Group I: Icotrokinra Dose 1 - Participants will receive icotrokinra dose 1. Participants who continue into a long term extension (LTE) will continue to receive icotrokinra dose 1.

Experimental: Group II: Icotrokinra Dose 2 - Participants will receive icotrokinra dose 2. Participants who continue into a LTE will continue to receive icotrokinra dose 2.

Placebo comparator: Group III: Placebo - Participants will receive placebo matched to icotrokinra and will cross over to receive icotrokinra dose 1 or dose 2. Participants who continue into the LTE will continue to receive icotrokinra dose 1 or dose 2.

Active comparator: Group IV: Active Reference Comparator - Participants will receive active reference drug. Participants who continue into a LTE will cross-over to receive icotrokinra dose 1 or dose 2.


Treatment: Drugs: Icotrokinra
Icotrokinra will be administered.

Treatment: Drugs: Placebo
Placebo will be administered.

Treatment: Drugs: Active reference comparator
Active reference drug will be administered.

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of Participants who Achieve an American College of Rheumatology (ACR) ACR 20 Response at Week 16
Timepoint [1] 0 0
Week 16
Secondary outcome [1] 0 0
Proportion of Participants Who Achieve Psoriatic Area and Severity Index (PASI) 75 Response at Week 16 Among Participants with Baseline Body Surface Area (BSA) Greater Than Equal to (>=) 3 Percent (%) and an IGA Score of >=2 at Baseline
Timepoint [1] 0 0
Week 16
Secondary outcome [2] 0 0
Proportion of Participants Who Achieve PASI 90 Response at Week 16 Among Participants with Baseline BSA >=3% and an IGA Score of >=2 at Baseline
Timepoint [2] 0 0
Week 16
Secondary outcome [3] 0 0
Proportion of Participants Who Achieve PASI 100 Response at Week 16 Among Participants with Baseline BSA >=3% and an IGA Score of >=2 at Baseline
Timepoint [3] 0 0
Week 16
Secondary outcome [4] 0 0
Proportion of Participants with an Investigator Global Assessment (IGA) Psoriasis Score of 0 or 1 And >=2 Grade Improvement From Baseline at Week 16 Among Participants with Baseline BSA >=3% and an IGA Score of >=2 at Baseline
Timepoint [4] 0 0
Week 16
Secondary outcome [5] 0 0
Proportion of Participants who Achieve an ACR 50 Response at Week 16
Timepoint [5] 0 0
Week 16
Secondary outcome [6] 0 0
Proportion of Participants who Achieve an ACR 70 Response at Week 16
Timepoint [6] 0 0
Week 16
Secondary outcome [7] 0 0
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score At Week 16
Timepoint [7] 0 0
From Baseline to Week 16
Secondary outcome [8] 0 0
Changes From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
Timepoint [8] 0 0
From Baseline to Week 16
Secondary outcome [9] 0 0
Proportion of Participants With Resolution of Enthesitis at Week 16 Among Those With Enthesitis at Baseline
Timepoint [9] 0 0
Week 16
Secondary outcome [10] 0 0
Change From Baseline in Enthesitis Score (LEI) at Week 16 in Participants With Enthesitis at Baseline
Timepoint [10] 0 0
From Baseline to Week 16
Secondary outcome [11] 0 0
Proportion of Participants With Resolution of Dactylitis at Week 16 Among Those With Dactylitis at Baseline
Timepoint [11] 0 0
Week 16
Secondary outcome [12] 0 0
Change From Baseline in Dactylitis Score at Week 16 in Participants With Dactylitis at Baseline
Timepoint [12] 0 0
From Baseline to Week 16
Secondary outcome [13] 0 0
Proportion of Participants who Achieve Minimal Disease Activity (MDA) at Week 16
Timepoint [13] 0 0
Week 16
Secondary outcome [14] 0 0
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 16
Timepoint [14] 0 0
From Baseline to Week 16

Eligibility
Key inclusion criteria
* Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study intervention and meet classification criteria for psoriatic arthritis (CASPAR) at screening
* Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) C-reactive protein (CRP) greater than or equal to (>=) 0.1 milligrams per deciliter (mg/dL) at screening from the central laboratory
* Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
* Have active plaque psoriasis with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with psoriasis
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
* Has previously received any biologic disease-modifying antirheumatic drugs (DMARDs) for PsA or psoriasis
* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of PsA), psychiatric, genitourinary, or metabolic disturbances
* Has known allergies, hypersensitivity, or intolerance to icotrokinra or its excipients
* Has other inflammatory diseases that might confound the evaluations of benefit of icotrokinra therapy, including but not limited to rheumatoid arthritis (RA), systemic lupus erythematosus, or lyme disease
* Participants with fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, would have potential to interfere with efficacy assessments

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Ipswich Hospital - Ipswich
Recruitment hospital [2] 0 0
Rheumatology Research Unit - Maroochydore
Recruitment hospital [3] 0 0
BJC Health - Parramatta
Recruitment hospital [4] 0 0
Queen Elizabeth Hospital - South Woodville
Recruitment hospital [5] 0 0
Royal Darwin Hospital - Tiwi
Recruitment postcode(s) [1] 0 0
4305 - Ipswich
Recruitment postcode(s) [2] 0 0
4558 - Maroochydore
Recruitment postcode(s) [3] 0 0
2150 - Parramatta
Recruitment postcode(s) [4] 0 0
5011 - South Woodville
Recruitment postcode(s) [5] 0 0
0810 - Tiwi
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
North Carolina
Country [5] 0 0
United States of America
State/province [5] 0 0
Pennsylvania
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
Argentina
State/province [7] 0 0
Buenos Aires
Country [8] 0 0
Argentina
State/province [8] 0 0
Ciudad de Buenos Aires
Country [9] 0 0
Argentina
State/province [9] 0 0
Ciudad de San Miguel de Tucuman
Country [10] 0 0
Argentina
State/province [10] 0 0
Córdoba
Country [11] 0 0
Argentina
State/province [11] 0 0
San Fernando
Country [12] 0 0
Argentina
State/province [12] 0 0
San Isidro
Country [13] 0 0
Bulgaria
State/province [13] 0 0
Haskovo
Country [14] 0 0
Bulgaria
State/province [14] 0 0
Pleven
Country [15] 0 0
Bulgaria
State/province [15] 0 0
Plovdiv
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Rousse
Country [17] 0 0
China
State/province [17] 0 0
Beijing
Country [18] 0 0
China
State/province [18] 0 0
Changchun
Country [19] 0 0
China
State/province [19] 0 0
Changsha
Country [20] 0 0
China
State/province [20] 0 0
Chengdu
Country [21] 0 0
China
State/province [21] 0 0
Chongqing
Country [22] 0 0
China
State/province [22] 0 0
Guangzhou
Country [23] 0 0
China
State/province [23] 0 0
Guiyang
Country [24] 0 0
China
State/province [24] 0 0
Linyi
Country [25] 0 0
China
State/province [25] 0 0
Nanchang
Country [26] 0 0
China
State/province [26] 0 0
Nantong
Country [27] 0 0
China
State/province [27] 0 0
Pingxiang
Country [28] 0 0
China
State/province [28] 0 0
Shanghai
Country [29] 0 0
China
State/province [29] 0 0
Shenzhen
Country [30] 0 0
China
State/province [30] 0 0
Shijiazhuang
Country [31] 0 0
China
State/province [31] 0 0
Suzhou
Country [32] 0 0
China
State/province [32] 0 0
Taiyuan
Country [33] 0 0
China
State/province [33] 0 0
Wenzhou
Country [34] 0 0
China
State/province [34] 0 0
Xi'an
Country [35] 0 0
China
State/province [35] 0 0
Zhenjiang
Country [36] 0 0
Czechia
State/province [36] 0 0
Brno
Country [37] 0 0
Czechia
State/province [37] 0 0
Brno-Židenice
Country [38] 0 0
Czechia
State/province [38] 0 0
Breclav
Country [39] 0 0
Czechia
State/province [39] 0 0
Hlucín
Country [40] 0 0
Czechia
State/province [40] 0 0
Karvina Frystat
Country [41] 0 0
Czechia
State/province [41] 0 0
Ostrava
Country [42] 0 0
Czechia
State/province [42] 0 0
Prague
Country [43] 0 0
Czechia
State/province [43] 0 0
Uherské Hradište
Country [44] 0 0
Czechia
State/province [44] 0 0
Zlín
Country [45] 0 0
Denmark
State/province [45] 0 0
Aarhus N
Country [46] 0 0
Denmark
State/province [46] 0 0
Esbjerg
Country [47] 0 0
Denmark
State/province [47] 0 0
Frederiksberg
Country [48] 0 0
Denmark
State/province [48] 0 0
Herning
Country [49] 0 0
Denmark
State/province [49] 0 0
Svendborg
Country [50] 0 0
Denmark
State/province [50] 0 0
Vejle
Country [51] 0 0
Germany
State/province [51] 0 0
Bad Bentheim
Country [52] 0 0
Germany
State/province [52] 0 0
Berlin
Country [53] 0 0
Germany
State/province [53] 0 0
Dresden
Country [54] 0 0
Germany
State/province [54] 0 0
Freiburg im Breisgau
Country [55] 0 0
Germany
State/province [55] 0 0
Hamburg
Country [56] 0 0
Germany
State/province [56] 0 0
Herne
Country [57] 0 0
Germany
State/province [57] 0 0
Langenau
Country [58] 0 0
Germany
State/province [58] 0 0
Minden
Country [59] 0 0
Germany
State/province [59] 0 0
Tübingen
Country [60] 0 0
Hong Kong
State/province [60] 0 0
Hong Kong
Country [61] 0 0
Hungary
State/province [61] 0 0
Budapest
Country [62] 0 0
Hungary
State/province [62] 0 0
Debrecen
Country [63] 0 0
Hungary
State/province [63] 0 0
Gyula
Country [64] 0 0
Hungary
State/province [64] 0 0
Kaposvár
Country [65] 0 0
Hungary
State/province [65] 0 0
Szeged
Country [66] 0 0
Hungary
State/province [66] 0 0
Szolnok
Country [67] 0 0
Hungary
State/province [67] 0 0
Veszprém
Country [68] 0 0
India
State/province [68] 0 0
Ahmedabad
Country [69] 0 0
India
State/province [69] 0 0
Bhubaneswar
Country [70] 0 0
India
State/province [70] 0 0
Hyderabad
Country [71] 0 0
India
State/province [71] 0 0
Kolkata
Country [72] 0 0
India
State/province [72] 0 0
Mumbai
Country [73] 0 0
India
State/province [73] 0 0
Mysuru
Country [74] 0 0
India
State/province [74] 0 0
New Delhi
Country [75] 0 0
India
State/province [75] 0 0
Noida
Country [76] 0 0
India
State/province [76] 0 0
Surat
Country [77] 0 0
Japan
State/province [77] 0 0
Fukuoka
Country [78] 0 0
Japan
State/province [78] 0 0
Kita Gun
Country [79] 0 0
Japan
State/province [79] 0 0
Nagoya
Country [80] 0 0
Japan
State/province [80] 0 0
Osaka
Country [81] 0 0
Japan
State/province [81] 0 0
Oita
Country [82] 0 0
Japan
State/province [82] 0 0
Sasebo
Country [83] 0 0
Japan
State/province [83] 0 0
Sendai
Country [84] 0 0
Japan
State/province [84] 0 0
tabashi City
Country [85] 0 0
Japan
State/province [85] 0 0
Tokyo
Country [86] 0 0
Japan
State/province [86] 0 0
Tsu
Country [87] 0 0
Poland
State/province [87] 0 0
Bialystok
Country [88] 0 0
Poland
State/province [88] 0 0
Bydgoszcz
Country [89] 0 0
Poland
State/province [89] 0 0
Elblag
Country [90] 0 0
Poland
State/province [90] 0 0
Gdynia
Country [91] 0 0
Poland
State/province [91] 0 0
Krakow
Country [92] 0 0
Poland
State/province [92] 0 0
Lodz
Country [93] 0 0
Poland
State/province [93] 0 0
Lublin
Country [94] 0 0
Poland
State/province [94] 0 0
Nadarzyn
Country [95] 0 0
Poland
State/province [95] 0 0
Olsztyn
Country [96] 0 0
Poland
State/province [96] 0 0
Torun
Country [97] 0 0
Poland
State/province [97] 0 0
Warsaw
Country [98] 0 0
Poland
State/province [98] 0 0
Wroclaw
Country [99] 0 0
Spain
State/province [99] 0 0
A Coruña
Country [100] 0 0
Spain
State/province [100] 0 0
Barcelona
Country [101] 0 0
Spain
State/province [101] 0 0
Córdoba
Country [102] 0 0
Spain
State/province [102] 0 0
Madrid
Country [103] 0 0
Spain
State/province [103] 0 0
Málaga
Country [104] 0 0
Spain
State/province [104] 0 0
Sabadell
Country [105] 0 0
Spain
State/province [105] 0 0
Santander
Country [106] 0 0
Spain
State/province [106] 0 0
Seville
Country [107] 0 0
Taiwan
State/province [107] 0 0
Hsinchu
Country [108] 0 0
Taiwan
State/province [108] 0 0
Kaohsiung City
Country [109] 0 0
Taiwan
State/province [109] 0 0
Tainan
Country [110] 0 0
Taiwan
State/province [110] 0 0
Taipei
Country [111] 0 0
Taiwan
State/province [111] 0 0
Taoyuan
Country [112] 0 0
Thailand
State/province [112] 0 0
Bangkok
Country [113] 0 0
Thailand
State/province [113] 0 0
Changwat Sara Buri
Country [114] 0 0
Thailand
State/province [114] 0 0
Phra Nakhon Si Ayutthaya
Country [115] 0 0
Thailand
State/province [115] 0 0
Songkhla

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country
Secondary sponsor
Nil

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.